全文获取类型
收费全文 | 55618篇 |
免费 | 3929篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 439篇 |
儿科学 | 2014篇 |
妇产科学 | 1932篇 |
基础医学 | 6771篇 |
口腔科学 | 717篇 |
临床医学 | 9289篇 |
内科学 | 10204篇 |
皮肤病学 | 840篇 |
神经病学 | 5068篇 |
特种医学 | 1050篇 |
外国民族医学 | 33篇 |
外科学 | 4975篇 |
综合类 | 739篇 |
一般理论 | 82篇 |
预防医学 | 7705篇 |
眼科学 | 761篇 |
药学 | 3152篇 |
1篇 | |
中国医学 | 102篇 |
肿瘤学 | 3790篇 |
出版年
2023年 | 314篇 |
2022年 | 458篇 |
2021年 | 1070篇 |
2020年 | 708篇 |
2019年 | 1153篇 |
2018年 | 1312篇 |
2017年 | 909篇 |
2016年 | 1025篇 |
2015年 | 1108篇 |
2014年 | 1533篇 |
2013年 | 2566篇 |
2012年 | 3653篇 |
2011年 | 3930篇 |
2010年 | 2110篇 |
2009年 | 1982篇 |
2008年 | 3448篇 |
2007年 | 3919篇 |
2006年 | 3807篇 |
2005年 | 3715篇 |
2004年 | 3610篇 |
2003年 | 3434篇 |
2002年 | 3221篇 |
2001年 | 546篇 |
2000年 | 436篇 |
1999年 | 541篇 |
1998年 | 712篇 |
1997年 | 568篇 |
1996年 | 489篇 |
1995年 | 411篇 |
1994年 | 426篇 |
1993年 | 417篇 |
1992年 | 362篇 |
1991年 | 344篇 |
1990年 | 327篇 |
1989年 | 263篇 |
1988年 | 271篇 |
1987年 | 281篇 |
1986年 | 251篇 |
1985年 | 254篇 |
1984年 | 274篇 |
1983年 | 266篇 |
1982年 | 323篇 |
1981年 | 294篇 |
1980年 | 254篇 |
1979年 | 189篇 |
1978年 | 179篇 |
1977年 | 193篇 |
1976年 | 160篇 |
1974年 | 135篇 |
1973年 | 136篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
171.
Christine B Ambrosone Mary K Nesline Warren Davis 《Cancer epidemiology, biomarkers & prevention》2006,15(9):1575-1577
The establishment of a biorepository with linkage to clinical and epidemiologic data will provide an invaluable resource for cancer research, including studies of cancer etiology, progression, and prognosis, as well as development of biomarkers for early detection. Developing an infrastructure for a biorepository linked to clinical, pathologic, and epidemiologic data requires significant efforts in strategic planning for efficient means to ascertain, identify, and consent participants, as well as guidelines for blood collection, processing, and storage while maintaining participant privacy rights. In this report, we present an approach to developing a Data Bank and Biorepository at our own institution, with discussion of elements to be considered when establishing such a bank. 相似文献
172.
173.
174.
Abdulbaqi Al-Toma Marije S Goerres Jos W R Meijer B Mary E von Blomberg Peter J Wahab Jo A M Kerckhaert Chris J J Mulder 《Clinical gastroenterology and hepatology》2006,4(11):1322-7; quiz 1300
BACKGROUND & AIMS: Refractory celiac disease (RCD) may be subdivided into RCD types I and II with phenotypically normal and aberrant intraepithelial T-cell populations, respectively. In RCD II, transition into enteropathy-associated T-cell lymphoma (EATL) is seen frequently. We have evaluated the effect of cladribine (2-CDA), a purine analogue inducing T-cell depletion, on clinical, histopathologic, and immunologic parameters, as well as the toxicity and side effects in a group of RCD II patients. METHODS: Between 2000 and 2005, 17 patients were included (8 men, 9 women). All patients had a clonal rearrangement of the T-cell receptor gamma gene and immunophenotyping showed an aberrant T-cell population lacking surface expression of CD3, CD8, and T-cell receptor alphabeta, in the presence of expression of surface CD103 and intracytoplasmic CD3. Treatment consisted of 2-CDA (0.1 mg/kg/day) intravenously for 5 days, given in 1-3 courses every 6 months depending on the response. RESULTS: All patients tolerated 2-CDA without serious side effects. Six patients (35.8%) showed a clinical improvement (weight gain, improvement of diarrhea, and hypoalbuminemia). In 10 patients (58.8%) a significant histologic improvement and in 6 patients (35.2%) a significant decrease in aberrant T cells was seen. Seven patients (41.1%) developed EATL and died subsequently. One patient died of progressive refractory state with emaciation. CONCLUSIONS: Treatment with 2-CDA in RCD II is feasible, well tolerated, and can induce clinical and histologic improvement as well as a significant decrease of aberrant T cells in a subgroup of patients, albeit it does not prevent EATL development. However, the earlier reported potential risk of precipitating an overt lymphoma should be taken into consideration. 相似文献
175.
Perioperative Hearing Impairment 总被引:4,自引:0,他引:4
176.
Anthracycline cardiotoxicity. 总被引:3,自引:0,他引:3
Anthracycline drugs have been widely used as chemotherapeuticagents against a range of cancers, including sarcomas, carcinomas,leukaemias, and lymphomas. However, cardiotoxic effects, inparticular the development of cardiomyopathy, have limited theirclinical use. The observation of dose-dependent cardiotoxicityhas resulted in a recommended empirical dose limit of 450 mg/m2of body surface area. Age, gender, pre-existing heart disease,hypertension, and mediastinal irradiation have also been implicatedas factors contributing to the development of doxorubicin-associatedcardiomyopathy. However, cardiotoxicity may still occur at relativelylow levels of drug administration, even in individuals withno additional risk factors, and the onset may be delayed bymany years.1 More recently, the use of trastuzumab, a monoclonalantibody directed against the HER2 receptor, has been 相似文献
177.
Dr. Mary S. Brady MD Carol F. Garfein MBA Jeanne A. Petrek MD Murray F. Brennan MD 《Annals of surgical oncology》1994,1(1):66-72
Background: Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years.
Methods: In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation).
Results: Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p<0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98).
Conclusions: Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.Presented at the 46th Annual Cancer Symposium of the Society of Surgical Oncology, Los Angeles, March 18–21, 1993. 相似文献
178.
179.
Sandra Lobo Jaroslav Cervenka Arnold London Mary Ella M. Pierpont 《American journal of medical genetics. Part A》1992,43(4):701-703
We report on a patient with interstitial deletion of 10q and compare her to 8 previously described patients, 2 of whom have chromosomal breakpoints similar to our patient. Minor anomalies including broad forehead, hypertelorism, strabismus, prominent philtrum, and “dysplastic” pinnae are present in our patient. Psychomotor retardation and hypotonia are universal findings in 10q interstitial deletion. Growth retardation, not present in our patient, is seen in some. These clinical findings are sufficiently distinct to suggest early chromosome studies. © 1992 Wiley-Liss, Inc. 相似文献
180.
Gangliosides of cultured astroglia 总被引:3,自引:0,他引:3
Michele Sbaschnig-Agler Henri Dreyfus William T. Norton Monique Sensenbrenner Muhammad Farooq Mary C. Byrne Robert W. Ledeen 《Brain research》1988,461(1):98-106
Cultured astrocytes prepared from newborn rat brain and 13-day-old chick embryonic brain were analyzed qualitatively and quantitatively for ganglioside content. All preparations contained approximately the same total level: 2.4-3.4 micrograms N-acetylneuraminic acid (NeuAc)/mg protein. In contrast, the value for primary cultures of neurons from chick embryonic brain was 5.9. The non-hexosamine-containing species, GM3 and GD3, comprised 75-85% of the total in astroglial cultures, the remainder consisting mainly of structural types other than the gangliotetraose series; choleragenoid assay revealed the latter to be virtually absent or to comprise at most a few percent. Deficiency of gangliotetraose synthesizing ability was indicated by the very low level of UDP-GalNac:GM3 N-acetylgalactosaminyltransferase detected in the cells. Treatment of cultured astrocytes with astroglial growth factor 2 or dibutyryl cyclic AMP caused little if any change in quantity or pattern of gangliosides. The large majority of cells stained in a manner characteristic of astrocytes: positive for glial fibrillary acidic protein, negative for galactosyl ceramides. Staining with cholera toxin and anti-GM1 antibody was essentially negative, as was that with tetanus toxin, A2B5 monoclonal antibody, and antibody to GD3. All evidence thus points to cultured astrocytes of rat and chick brain containing appreciable gangliosides, most of which are GM3 and GD3 with the majority of the remainder comprising structures other than the gangliotetraose type. 相似文献